This record was last updated January 2, 2020 (before its estimated December 2021 completion). Its status may not reflect the trial's current state.
Summary
Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodule up to 50Gy. The pelvic lymph nodes and seminal vesicles will also receive 25 Gy in 5 weekly fractions.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2019-12-26.